Overview

A Randomised Trial of Dolutegravir (DTG)-Based Antiretroviral Therapy vs. Standard of Care (SOC) in Children With HIV Infection Starting First-line or Switching to Second-line ART

Status:
Active, not recruiting

Trial end date:
2023-05-01

Target enrollment:

Participant gender:

Summary

A new anti-HIV medicine (Dolutegravir) combined with 2 currently used anti-HIV medicines is non-inferior to the standard combination of medicines used in terms of efficacy and better in terms of toxicity.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

PENTA Foundation

Collaborators:

Institut National de la Santé Et de la Recherche Médicale, France
Medical Research Council Clinical Trials Unit at University College London (MRC CTU at UCL)
Program for HIV Prevention and Treatment (PHPT)